Therapeutic suppression of constitutive and inducible JAK\STAT activation in head and neck squamous cell carcinoma
- PMID: 20192118
Therapeutic suppression of constitutive and inducible JAK\STAT activation in head and neck squamous cell carcinoma
Abstract
The oncogenic role of STAT3 has been elucidated in a number of human malignancies including leukemia, lymphoma, malignant glioma and cancers of the breast, lung, and head and neck (HNSCC). Here we show that WP1066 has profound anti-neoplastic effects in HNSCC, mediated in part by suppression of JAK2-STAT3 signaling. WP1066 inhibited constitutive and inducible STAT3 phosphorylation in both dose- and time-dependant manners. Further, the nuclear translocation of STAT3 was completely inhibited, resulting in decreased DNA binding activity. In vivo testing of WP1066 in a nude mouse orthotopic model of HNSCC demonstrated significant anti-tumor effects, with histological evidence of decreased cellular proliferation and angiogenesis. Collectively, these data suggest that WP1066 suppresses squamous cell carcinoma cell growth, in part through its effects on JAK-STAT pathways, and establishes this small molecule as potentially efficacious agent in the treatment of HNSCC.
Similar articles
-
Targeting constitutive and interleukin-6-inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane).Int J Cancer. 2006 Sep 15;119(6):1268-75. doi: 10.1002/ijc.21967. Int J Cancer. 2006. PMID: 16642480
-
Inhibition of JAK2/STAT3 reduces tumor-induced angiogenesis and myeloid-derived suppressor cells in head and neck cancer.Mol Carcinog. 2018 Mar;57(3):429-439. doi: 10.1002/mc.22767. Epub 2017 Dec 30. Mol Carcinog. 2018. PMID: 29215754
-
WP1066 suppresses macrophage cell death induced by inflammasome agonists independently of its inhibitory effect on STAT3.Cancer Sci. 2017 Mar;108(3):520-527. doi: 10.1111/cas.13154. Cancer Sci. 2017. PMID: 28035720 Free PMC article.
-
The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations.Oral Oncol. 2016 May;56:84-92. doi: 10.1016/j.oraloncology.2015.11.022. Epub 2015 Dec 28. Oral Oncol. 2016. PMID: 26733183 Free PMC article. Review.
-
Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.Drug Resist Updat. 2010 Jun;13(3):67-78. doi: 10.1016/j.drup.2010.04.001. Epub 2010 May 14. Drug Resist Updat. 2010. PMID: 20471303 Review.
Cited by
-
Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance.J Transl Med. 2017 Sep 6;15(1):189. doi: 10.1186/s12967-017-1289-2. J Transl Med. 2017. PMID: 28877725 Free PMC article.
-
TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma.Oncogene. 2010 Apr 8;29(14):2047-59. doi: 10.1038/onc.2009.486. Epub 2010 Jan 18. Oncogene. 2010. PMID: 20101235 Free PMC article.
-
BDNF and its signaling in cancer.J Cancer Res Clin Oncol. 2023 Jun;149(6):2621-2636. doi: 10.1007/s00432-022-04365-8. Epub 2022 Sep 29. J Cancer Res Clin Oncol. 2023. PMID: 36173463 Free PMC article. Review.
-
JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.Neoplasia. 2015 Mar;17(3):256-64. doi: 10.1016/j.neo.2015.01.003. Neoplasia. 2015. PMID: 25810010 Free PMC article.
-
A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma.CNS Oncol. 2022 Jun 1;11(2):CNS87. doi: 10.2217/cns-2022-0005. Epub 2022 May 16. CNS Oncol. 2022. PMID: 35575067 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous